BioLight Life Sciences Investments announced today that on October 20, 2015, its subsidiary DiagnosTear Ltd., in which BioLight holds 70% of the issued and outstanding share capital, notified DiagnosTear that a third year approval for a grant from the Israeli Office of the Chief Scientist for a project with respect to the development of a diagnostic test intended for the diagnosis and monitoring of treatment of dry eye syndrome, was received and approved.
Link to Newsroom